Abstract: Round cell tumors of bone are a divergent group of neoplasms that largely constitute Ewing sarcoma/primitive neuroectodermal tumor, small cell osteosarcoma, Langerhans cell histiocytosis, mensenchymal chondrosarcoma, and hematopoietic malignancies including lymphoma and plasmacytoma/myeloma, along with metastatic round cell tumors including neuroblastoma, rhabdomyosarcoma, and small cell carcinoma. These lesions share many histomorphologic similarities and often demonstrate overlapping clinical and radiologic characteristics, but typically have a diverse clinical outcome, thus warranting differing therapeutic modalities/regimens. Recent advances in molecular and cytogenetic techniques have identified a number of additional novel entities, including round cell sarcomas harboring CIC-DUX4 and BCOR-CCNB3 fusions, respectively. These novel findings have not only enhanced our understanding of the pathogenesis of round cell tumors, but also allowed us to reclassify some entities with potential therapeutic and prognostic significance. This article provides an overview focusing on recent molecular genetic advances in primary, nonhematologic round cell tumors of bone.
P
rimary round cell tumors of bone represent a diverse group of neoplasms. They can occur in any age group but demonstrate different age peaks for given tumor types, although predominantly affecting children and young adults. 1 The most common round cell tumors of bone include Ewing sarcoma/primitive neuroectodermal tumor (PNET), small cell osteosarcoma, Langerhans cell histiocytosis (LCH), mensenchymal chondrosarcoma, and hematopoietic malignancies such as lymphoma and plasmacytoma/myeloma. Further, there are 2 recently identified unique round cell sarcomas characterized by harboring CIC-DUX4 and BCOR-CCNB3 fusions, respectively. In addition, other small, blue, round cell tumors typically occurring in soft tissue, including neuroblastoma and rhabdomyosarcoma, frequently relapse in bone in the first instance. Furthermore, metastatic small cell carcinoma in bone is not an infrequent event. Although these tumors share many histomorphologic similarities, each entity has its unique clinical, radiologic, and pathologic characteristics.
Recurrent chromosomal rearrangements are characteristic features of a number of bone and soft-tissue sarcomas. Identification and characterization of specific molecular genetic abnormalities have revolutionized the diagnosis of sarcomas and also provided insight into potential therapeutic targets as well as prognostic biomarkers. To that end, newer entities have been recently identified along with allowing reclassification of a number of previously established tumor types. In this article, we provide an overview focusing on recent molecular genetic advancements in primary, nonhematologic round cell tumors of bone.
EWING SARCOMA/PRIMITIVE NEUROECTODERMAL TUMOR Clinical and Radiologic Features
The Ewing sarcoma/PNET family of tumors was originally thought to be 2 separate entities with the latter demonstrating neuroectodermal differentiation by histomorphology, immunohistochemistry, or electron microscopy. It is now generally accepted that Ewing sarcoma of bone, extraosseous Ewing sarcoma, PNET, and Askin tumor (PNET arising in the chest wall) are histologic variants of the same tumor spectrum sharing the common genetic abnormalities characterized by a balanced translocation, which results in EWSR1 gene rearrangement in almost all (B90%) of cases. Thus, it is relatively unimportant to designate a particular tumor as Ewing sarcoma or PNET.
Ewing sarcoma accounts for 6% to 8% of primary malignant bone tumors and is the second most common bone malignancy in children and young adults, after osteosarcoma. 2 The tumor notably occurs more commonly in whites than other ethnic groups, with a slight male predominance (sex ratio 1.4:1). 3 It predominantly affects patients between 5 and 20 years, although patients older than 30 years of age are also rarely involved. Congenital Ewing sarcoma has also been reported. 4 The cell of origin of Ewing sarcoma has long been the focus of intensive research. There is currently lack of consensus regarding the cell of origin in Ewing sarcoma, while mesenchymal stem cells or neural crest stem cells are currently favored at this point. [5] [6] [7] [8] [9] The most common clinical presentation is pain with or without a mass. Intermittent fever, anemia, and pathologic fracture are uncommon clinical symptoms/signs. The classic location is the diaphysis or metaphysis of long, tubular bones, although it may also arise in the axial bones such as the skull, vertebra, ribs, scapula, pelvis, and short tubular bones of hands and feet. 3 Epiphyseal Ewing sarcomas have been recently reported. [10] [11] [12] Up to 20% of cases are extraskeletal. 3 On imaging studies, the lesion typically presents as a permeative intramedullary lesion, most often osteolytic in nature (Figs. 1, 2) . The tumor frequently penetrates the cortex into the surrounding soft tissue as it progresses. An active periosteal reaction as manifested by multilayered new bone formation, when present, is characteristic and gives the rise to the appearance of "onion skinning" on conventional radiographs.
Pathologic Features
The gross pathologic features of Ewing sarcoma are typically those of an ill-defined mass with destructive borders. Surgical intervention/amputation nowadays is invariably performed after neoadjuvant chemotherapy following biopsy confirmation of the pathologic diagnosis. Thus, the resected specimen often shows a necrotic mass if the tumor has a complete or near-complete response to the therapeutic agents (Fig. 3) . Microscopically, the tumor typically appears as solid sheets of uniform small, blue, round cells commonly with a vascular-rich stroma and minimal extracellular matrix (Fig. 4A) . Geographic necrosis is typical and frequently results in a pattern of perivascular distribution of viable cells (Fig. 4B) . At higher magnification, the tumor cells are slightly larger than normal lymphocytes, and have scant cytoplasm and indistinctive cell membranes. The tumor cell nuclei demonstrate fine chromatin with or without inconspicuous nucleoli (Fig. 4C) . The cytoplasm is typically rich in glycogen, which can be highlighted by a periodic acid-Schiff (PAS) stain. Perivascular rosettes and Homer-Wright pseudorosettes (tumor cells surrounding a central core filled with eosinophilic extracellular material) may be seen in a subset of cases. The reported morphologic variants include large cell (atypical Ewing sarcoma), admantinoma-like, sclerosing (Fig. 4D) , and spindle cell sarcoma-like. 1, 13 Immunophenotypically, diffuse membranous expression of CD99 is characteristic for Ewing sarcoma but not specific (Fig. 4E) . Nuclear FLI1 expression is seen in a majority of Ewing sarcoma cases with the t(11;22)(q24;q12) chromosomal translocation (Fig. 4F ). ERG nuclear immunoreactivity is seen in a small subset of cases harboring the t(21;22)(q22;q12) translocation. Focal expression of cytokeratin can be seen in up to 30% of cases. 3, 13 Of important note, FLI1 expression is not specific for Ewing sarcoma. In addition to its utility as an endothelial marker, the protein is also expressed in the great majority of lymphoblastic lymphomas (which are also CD99 positive) as well as anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma. 14 FLI1 is also expressed in a small subset of melanomas, Merkel cell carcinomas, synovial sarcomas, and carcinomas of lung and breast. 15 However, FLI1 may be useful to distinguish Ewing sarcoma from small cell osteosarcoma and mesenchymal chondrosarcoma, 2 other small, blue, round, cell tumors of bone in children, which are devoid of that molecule.
Molecular Genetics
The molecular genetic hallmark of Ewing sarcoma family tumors is the somatic reciprocal chromosomal translocations that lead to fusions of the EWSR1 (also known as EWS) gene on chromosome 22 with a member of the ETS (E26 transformation specific) transcription factor FIGURE 2. An axial CT image of the lesion seen in Figure 1 demonstrates cortical erosion and significant cortical thickening, with a soft-tissue mass in the medial aspect. family of genes. EWS is a member of the TET family of RNA-binding proteins, which also include FUS (TLS) and TAF15. The ETS family proteins consist of transcription factors characterized by the presence of a highly conserved 85 amino acid DNA-binding domain (ETS domain), and function as signal-dependent transcriptional regulators controlling cell proliferation and differentiation. The resulting EWS-ETS chimeric oncoproteins have been proved to display an array of downstream target molecules that contribute to tumorigenesis. These translocations, detected by a reverse transcription-polymerase chain reaction (RT-PCR) or fluorescent in situ hybridization (FISH), can be used for the diagnosis of primary tumor and detection of metastatic or residual disease in tissue, body fluid, and peripheral blood (Fig. 5) . The chromosomal rearrangements found in Ewing sarcoma family tumors to date are summarized in Table 1 .
The overwhelming majority of Ewing sarcomas are characterized by EWSR1 fusions with FLI1 gene on chromosome 11, reportedly identified in 85% of cases. The resulting fusion protein EWS-FLI1 contains the aminoterminus of EWSR1 and the carboxy-terminus of FLI1. This in-frame fusion protein acts as an oncogene through its function as an aberrant transcription factor. The recent advancements in molecular biology have enabled the identification of a large number of target genes dysregulated by EWS-FLI1 in Ewing sarcoma. Some of the upregulated genes, including NR0B1, NKX2.2, and GLI1, have been demonstrated to play a critical role in the process of EWS-FLI1-mediated oncogenic transformation. 28 The growing list of target genes suggests that EWS-FLI1 modulates a whole network of downstream effector genes to accomplish oncogenesis of Ewing sarcoma.
A number of alternative EWS-ETS fusions have been identified in Ewing sarcoma, of which the most common translocation is t(21;22)(q12;q12), found in approximately 10% of Ewing sarcoma cases, which gives rise to the fusion of EWSR1 to ERG. Tumors expressing the EWS-ERG fusion lack expression of EWS-FLI. A retrospective study revealed no significant differences in clinical characteristics or survival outcomes between EWS-FLI1 and EWS-ERG Ewing sarcoma cases. 29 These findings suggest that the 2 fusion proteins are capable of activating similar oncogenic pathways to drive the pathogenesis of Ewing sarcoma. Other recently identified alternative fusion partner genes of ETS family derivation include ETV1, ETV4, and FEV, accounting for <1% of cases. Once again, the fact of mutual exclusivity of various translocations in Ewing sarcoma suggests that these chimeric proteins may substitute for each other in the signaling pathways of oncogenesis.
Further added to the complexity of molecular genetics in Ewing sarcoma, EWSR1 may be rarely replaced by another member of the TET family of proteins, FUS, which results in FUS-ERG and FUS-FEV fusions. Conceptually, these fusions are likely to functionally recapitulate the EWS-FLI fusion by creating generic "TET-ETS" fusion proteins. Consequently, one can also imagine the identification of additional novel TET-ETS fusions partners, such as TAF15-ETS. However, these fusions, if they exist, would be exceedingly rare and unable to be detected by the currently utilized diagnostic methodologies, as break-apart FISH for EWSR1 or RT-PCR analysis for EWSR1-FLI1 and EWSR1-ERG are typically only what are searched for in Ewing sarcoma.
More recently, rare small, blue, round cell tumors have been discovered to harbor fusions between EWSR1 and the molecules of additional non-ETS family members, including NFATc2, POU5F1, SMARCA5 (also known as SNF2H), PATZ, ZSG, and SP3. These tumors are sometimes labeled as "Ewing-like sarcomas" as controversies remain as to whether these tumors should be classified as Ewing sarcoma, or represent separate tumor types. 28 Nonetheless, these tumors are currently treated clinically in a similar manner as classic Ewing sarcomas. Given that fusions of EWSR1 and ETS family members are specific to Ewing sarcoma, but combinations of EWSR1 with other genes result in the pathogenesis of other recognized malignancies (such as EWSR1-WT1 for desmoplastic small round tumor and EWSR1-ATF1 for clear cell sarcoma), it appears that the partner gene, rather than EWSR1, is responsible for the morphologic tumor type. Furthermore, a Ewing-like sarcoma having FLI1 immunoreactivity and harboring a t(18;19)(q23;q13.2) translocation was recently reported, thus deserving further investigation. 30 Other recently reported molecular alterations include single nucleotide polymorphism in the EWSR1 gene, 31 and a number of frequently methylated genes with yet further potential prognostic implications. 32 
Treatment and Prognosis
Ewing sarcoma displays a high propensity to metastasize to distant organs, with the most common sites being lung, bone, and bone marrow. It is believed that the vast majority of patients harbor micrometastatic disease, as the relapse rate for surgically resected Ewing sarcoma cases without systemic chemotherapy hovers the border of 90%. 28 The current standard of care for Ewing sarcoma patients is multimodal treatment, including systemic chemotherapy along with either surgery and/or radiation for control of the primary disease. The clinicopathologic factors proved to be associated with prognosis include tumor stage, anatomic location, and the size of tumor. The extent of neuroectodermal differentiation does not appear to predict outcome. 33 Although early studies suggested prognostic difference for the EWS-ETS fusion type, it is no longer thought to be of prognostic significance. 34, 35 ROUND CELL SARCOMA HARBORING CIC-DUX4 FUSION
There is a small subset of sarcomas that clinically and histologically mimic Ewing sarcoma/PNET but fail to demonstrate any of the reported cytogenetic abnormalities described above. These tumors have also been historically labeled as Ewing-like sarcomas. Recent molecular genetic advances have led to identifying tumors with primitive round cell morphology harboring fusions lacking rearrangement of EWSR1 or other TET family members. In 2006, 2 cases of "Ewing-like sarcoma" were found to harbor a recurrent chromosomal translocation t(4;19)(q35;q13), which resulted in fusion between CIC, a human homolog of Drosophila capicua, which encodes a high mobility group box transcription factor, and DUX4, a double homeodomain gene. 36 In fact, a rearrangement involving 4q35 was previously found in round cell tumors diagnosed as embryonal rhabdomyosarcoma. 37, 38 Along the same line, the t(4;19)(q35;q13) translocation has previously been reported in a pediatric tumor as a t(11;22)-negative PNET 39 and in another pediatric tumor characterized as malignant sarcoma with differentiation toward extraskeletal mesenchymal chondrosarcoma, as electron microscopy indicated chondroblastic differentiation. 40 The CIC-DUX4 fusion was identified in a number of subsequent studies utilizing highthroughput array comparative genomic hybridization, spectral karyotyping, FISH, RACE, RT-PCR, and/or long-range DNA PCR techniques. [41] [42] [43] [44] The CIC-DUX4 fusion product was shown to function as a transcription factor that upregulates gene expression of the PEA3 (polyoma enhancer activator-3) subfamily of ETS, including ETV1, ETV4, and ETV5. 36 Interestingly, DUX10, a DUX4 homolog located on chromosome 10q26.3, was shown to be another fusion partner for CIC but reported to cause no significant difference with regard to histology or clinical behavior from those sarcomas carrying CIC-DUX4 fusions. 44 These findings have clarified the function of CIC, in which the PEA3 subclass of ETS family proteins plays an essential role in tumorigenesis through mechanisms different from those involving EWS-ETS chimeras. FIGURE 5 . FISH analysis for EWSR1 gene rearrangement using a dual-color, break-apart probe is highly specific for Ewing sarcomas in the appropriate clinicopathologic setting, with variable sensitivities. In this technique, the red and green probes each bind to sequences upstream and downstream of the loci of interest. In contrast to the presence of only a secondary color (yellow) in normal interphase nuclei, one of the yellow signals in a neoplastic cell carrying a reciprocal translocation split, resulting in separated primary color (red and green) signals, in addition to the yellow signal from the normal chromosome (photograph courtesy of Dr Shuko Harada). 
To date, a total of 34 cases of round cell sarcomas harboring a t(4;19)/t(10;19) translocation or rearrangements involving 4q35 or 19q13 have been reported in the English literature (Table 2 ). There is a wide age distribution ranging from 5 to 62 years, with an equal sex distribution (M:F = 1.1:1) in these tumors. All reported cases were soft tissue based, except 1 with peritonsillar and mandible involvement and another involving bone by direct extension. 44 Interestingly, 1 case showed a t(4;22)(q35;q12) translocation resulting in a EWSR1-DUX4 fusion that immunophenotypically demonstrated skeletal muscle differentiation. 38 Thus, it remains uncertain whether such lesions should be named "Ewing sarcoma," "rhabdomyosarcoma," or "round cell sarcoma with CIC/ DUX4 rearrangement." Of note, the last patient discussed had the longest disease-free survival (6 y) among those with rearrangements involving 4q35 and/or 19q13. Moreover, skeletal muscle differentiation has now also been demonstrated in another round cell tumor harboring t(4;19)(q35;q13)/CIC-DUX4. 44 Histologically, CIC-DUX4 sarcomas exhibit distinctive and reproducible morphology. Virtually all tumors are comprised of small, blue, round cells with variable degree of geographic necrosis, along with mild nuclear pleomorphism, coarse chromatin, prominent nucleoli, clear cytoplasm, and focal extracellular myxoid matrix. Rare reports describe areas of spindle cells. 41, 44 Immunophenotypically, these tumors reflect an undifferentiated phenotype. The vast majority of reported cases showed CD99 immunoreactivity, ranging from focal and/or weak to diffuse and/or strong. Most tumors were focally positive for S-100 protein. Desmin, myogenin, cytokeratin, and EMA reactivity was found in rare cases. Interestingly, FLI1 positivity was found in 1 case. 41 A recent study, reported only in abstract form, performed immunohistochemical and molecular analysis of 19 CIC-DUX4 sarcomas with no detailed clinical information provided. 48 The study showed that in addition to focal and weak CD99 expression in all cases, WT-1 was highly sensitive (100%), thus providing a useful clue in the differential diagnosis with Ewing sarcoma, which typically lacks WT-1 expression. Frequent FLI1 (100%) and occasional ERG (18%) expression were seen in CIC-DUX4 sarcomas, thus representing diagnostic pitfalls. Further, gene expression profiling revealed a distinct gene signature associated with CIC-DUX4 sarcomas with upregulation of ETS family transcription factors ETV1, ETV4, and ETV5 among the top differentially upregulated genes compared with Ewing sarcomas. The findings were reiterated by a separate independent abstract, in which ETV1, ETV4, and ETV5 expression were seen in all 6 cases of CIC-DUX4 sarcoma by use of a chromogenic RNA in situ hybridization technique. 49 Although occasional CIC-DUX4 sarcomas showed no evidence of disease after chemotherapy over a relatively short period of follow-up, the majority of cases demonstrated a rapidly progressive malignant phenotype with high disease-associated mortality. The collective findings thus far support that round cell sarcomas characterized by CIC rearrangements represent a novel entity on the basis of divergent clinical and pathologic features, and should be distinguished from Ewing sarcoma/PNET. A definitive diagnosis of "Ewing-like" sarcomas with lack of rearrangements of EWSR1 or other TET family members thus requires further cytogenetic or molecular confirmatory tests.
ROUND CELL SARCOMA HARBORING BCOR-CCNB3 FUSION
More recently, a new subtype of bone sarcoma has been defined by the presence of a BCOR-CCNB3 gene fusion. In 2012, a fusion of BCL6 corepressor (BCOR) and CCNB3, which are nonadjacent genes on the X chromosome, was identified by paired-end RNA sequencing in 4 cases of bone sarcomas that clinically and morphologically would be classified in the Ewing sarcoma family tumors but lack the canonical EWSR1-ETS translocation. 50 A screen of 594 sarcomas lacking the most common diagnostic fusions resulted in identification of 24 cases that harbored the BCOR-CCNB3 fusion, suggesting that this translocation may represent a distinct entity of sarcomas.
CCNB3 (cyclin B3; Xp11.22) encodes an early meiotic cyclin that is only expressed in the testis during spermatogenesis. In contrast, BCOR (BCL6 corepressor; Xp11.4) encodes a ubiquitously expressed protein with activity in mesenchymal stem cells. Thus, the distinct fusion of these 2 genes suggested a possible mechanism whereby ectopic activation of CCNB3 drives tumorigenesis and progression. Further supporting the potential oncogenic function of CCNB3, overexpression of BCOR-CCNB3 or truncated CCNB3 was found to activate NIH3T3 cells in the S phases of the cell cycle. 50 Clinical and pathologic analysis of the tumors harboring a BCOR-CCNB3 fusion revealed that most of these tumors were "Ewing-like," undifferentiated small, round, blue cell tumors. Of note, all tumors but 5 (80%) were localized to bone, and all occurred in adolescents or young adults, ranging from 6 to 26 years with a median age of 13 years and a male to female ratio of 2:1. The tumors affected preferentially long bones, the spine, and pelvis. In contrast to Ewing sarcoma, approximately half of the cases lacked strong membrane positivity for CD99. One third of patients died of disease or had distant relapse.
Gene expression profiling and single-nucleotide polymorphism array analysis revealed that these tumors were genetically distinct from Ewing sarcoma and other common pediatric malignancies, including osteosarcoma, rhabdomyosarcoma, synovial sarcoma, neuroblastoma, malignant rhabdoid tumor, and desmoplastic round cell tumors. In particular, most of the well-known EWSR1-FLI1 target genes, such as NR0B1, CAV1, CAV2, PRKCB, NKX2-2, IGFBP3, IGFBP5, IGFBP7, CCK, and MYC, which have been shown to have critical roles in Ewing sarcoma oncogenesis, were not expressed in the BCOR-CCNB3-positive tumors.
Further, all BCOR-CCNB3-positive tumors tested exhibited strong nuclear CCNB3 immunoreactivity in contrast to the 25 BCOR-CCNB3-negative cases that completely lacked staining, highlighting the potential utility of this marker as a diagnostic tool. Thus, the findings suggest that sarcomas harboring BCOR-CCNB3 fusion may not only have a unique oncogenic process but may also be amenable to a simple immunohistochemistry-based diagnostic test. Further studies are needed to uncover the downstream consequence of this fusion. A potential relationship of this tumor type and CIC-DUX4 fusion-positive sarcomas may also be important to consider.
SMALL CELL OSTEOSARCOMA Clinical and Radiologic Features
Small cell osteosarcoma comprises approximately 1.5% of all osteosarcomas. The variant has a wide age distribution but is more commonly seen in the second decade of life. The majority occurs in the metaphysis of long bones. The clinical and radiologic features of small cell osteosarcoma are similar to those of conventional osteosarcoma (Fig. 6) , whereas it reportedly has a slightly worse prognosis than the latter. 51 
Pathologic Features
The histomorphologic features of small cell osteosarcoma combine those of osteosarcoma and Ewing sarcoma. The tumor is typically composed of cells with round to oval and, less frequently, short-spindled nuclei and are generally hyperchromatic (Fig. 7) . All cells have scanty cytoplasm. The nuclear size may vary from smaller ones equivalent to those of Ewing sarcoma, to the larger ones comparable with large cell lymphoma. Nucleoli are rarely seen and are typically small, if present. A prominent hemangiopericytoma-like growth pattern is not uncommon. A perivascular growth pattern can also be present, similar to that seen in a subset of Ewing sarcoma cases. The diagnosis of small cell osteosarcoma requires the presence of osteoid/bone matrix production, which is frequently not prominent and more commonly arranged in a lace-like manner. 13 Mitotic figures are variably present. There is no specific immunophenotype for small cell osteosarcoma. Tumor cells may variably express CD99, thus the latter should not be used in distinguishing it from Ewing sarcoma.
Molecular Genetics
To date, no recurrent molecular genetic abnormalities have been deteted in small cell osteosarcom in the largestscaled study of its kind. 52 Like other osteosarcomas, it can show a myriad of cytogenetic and molecular genetic abnormalities. 53 However, the t(11;22)(q24;q12) translocation typical of Ewing sarcoma was reported in 1 case of small cell osteosarcoma in 1990. 54 Recently, a case of small cell osteosarcoma with a EWSR1 rearrangement was detected by interphase FISH. 55 A EWSR1-CREB3L1 fusion transcript has been demonstrated in a multifocal small cell osteosarcoma, and the corresponding chimeric gene was confirmed by sequencing of the genomic breakpoint between EWSR1 and CREB3L1. 56 Although it remains unclear whether a round cell tumor demonstrating bone formation and harboring a EWSR1 rearrangement should be classified as small cell osteosarcoma or Ewing sarcoma, these observations suggest a possible relation between the molecular mechanisms of the 2 tumor types, thus deserving further investigation. Complex structural rearrangements of chromosomes 6, 16, and 17 and monoallelic deletion of TP53 was found in 1 tumor. 57 
LANGERHANS CELL HISTOCYTOSIS
LCH, formerly known as eosinophilic granuloma and Histiocytosis X, is a rare disease resulting from clonal proliferation of pathologic Langerhans cells. LCH of bone may be unifocal (monostotic) or multifocal (polyostotic), or may present as the bone manifestation of a systemic disease known as Letterer-Siwe disease, although there are those FIGURE 6 . A pelvic CT image demonstrates a lytic lesion in the left ilium. This small cell osteosarcoma is not typical for osteosarcoma because there is very little mineralized matrix produced. who argue this later form is different; more akin to malignant histiocytosis of infancy.
The pathogenesis of LCH has long been controversial. There are ongoing debates as to whether LCH is a reactive or neoplastic process. Langerhans cells are a type of dendritic cells of the skin and mucosa. The term LCH is itself controversial because there are morphologic, immunophenotypic, and gene expression differences between Langerhans cells of the skin/mucosa and those in the lesions of LCH. 58, 59 Early arguments against the neoplastic nature of LCH included the occurrence of spontaneous remissions and a generally favorable prognosis, especially in the monostotic form. 60 However, the demonstration of the clonal population of LCH cells, along with the fact of successful treatment of a subset of disseminated diseases with chemotherapy, are all consistent with a neoplastic process. [61] [62] [63] Although the clonality does not fully prove a neoplastic process, the recent findings of reproducible molecular genetic abnormalities support the contention to characterize LCH as a malignancy. 64 
Clinical and Radiologic Features
LCH accounts for <1% of all bone tumors. It can occur at all age groups, but is predominantly seen in infants, young children, and teenagers, and is exceedingly rare in patients older than 30 years. Boys are affected more often than girls, with a male-to-female ratio of 2:1. 65 Although any bone can be involved by LCH, the most frequently affected bone is skull. Other common sites of involvement in children include the femur, pelvis, and mandible. The rib is the most frequently involved site in adults. The most common clinical presentation is pain and/or swelling of affected area, rarely with pathologic fracture. Imaging studies generally show a pure lytic intramedullary lesion with well-defined margins and a periosteal reaction (Fig. 8) . In the skull, a "hole in a hole" appearance is characteristic. 13, 65 
Pathologic Features
Histologically, LCH is typically a cellular lesion composed of loose aggregates of multinucleated giant cells in a mixed inflammatory background with prominent eosinophils. The lesional Langerhans cells are intermediatesized, histiocytic-appearing mononuclear cells with indistinct cell borders, clear to eosinophilic cytoplasm, and vesicular nuclei with occasional nuclear grooves (Fig. 9) . These cells tend to exist in small nests or clusters but not diffusely. Large collections of eosinophils (a so-called eosinophilic "abscess") may be present. Multinucleated giant cells are frequent seen and may be prominent in areas. Langerhans cells typically show nuclear and cytoplasmic immunoexpression for S-100 protein, whereas CD1a and CD207 (Langerin) immunoreactivity in a distinct membranous pattern is more specific. The unique ultrastructural finding of intracytoplasmic inclusions known as "Birbeck granules" is diagnostic but usually not needed.
Molecular Genetics
Molecular genetic studies utilizing X-linked polymorphic DNA probes have demonstrated the clonality of nonpulmonary LCH. 63 A recent study has identified the first recurrent gain-of-function mutation (V600E) in the gene encoding B-Raf, an oncoprotein of the Raf family protein kinases. It was detected in 57% (35/61) of LCH cases. 64 The BRAF V600E was more commonly seen in patients younger than 10 years (76%) than in patients aged 10 and older (44%). This finding was further confirmed by other independent studies. 66, 67 The BRAF mutant genotype (illustrated in Fig. 10 ) was not found to be associated with any clinical characteristics of LCH such as site or stage, nor activation status of the downstream signaling molecules (ie, mitogen-activated protein kinase) in the lesional Langerhans cells. Thus, the mutation may affect LCH at earlier stage of pathogenesis or there may be other routes of Ras pathway activation (ie, through crosstalk with other pathways). It is of further interest that a possible clonal relationship has been demonstrated in coexistent LCH and acute leukemia of ambiguous or myeloid lineage in adult patients. All these cases exhibited geographic intermingling of the LCH and acute leukemia and shared unique features including extramedullary leukemic involvement of lymph nodes in all cases with LCH only present in sites involved by acute leukemia. 68 Thus, the findings suggest a common underlying neoplastic hematopoietic stem cell. Nonetheless, while the role for BRAF in LCH pathogenesis remains to be defined, this is not only an important niche from which to further investigate the biology of LCH, but also provides a potential tool for targeted therapy of disseminated disease.
Treatment and Prognosis
The prognosis of monostotic and limited polyostotic LCH is generally excellent. Spontaneous regression is not uncommon. Poor prognosis is associated with disseminated disease involving viscera, which may be fatal and is typically seen in patients younger than 2 years of age. 65 
MESENCHYMAL CHONDROSARCOMA Clinical and Radiologic Features
Mesenchymal chondrosarcoma is a rare but highly malignant tumor, accounting for <3% of all primary chondrosarcomas. It may occur at any age, with a peak incidence in the second and third decades of life. The tumor shows a widespread skeletal distribution but may also primarily affect extraskeletal sites. It more commonly arises in the axial skeleton, including craniofacial bones, ribs, ilium, and vertebrae. 69 Oncogenic osteomalacia secondary to mesenchymal chondrosarcoma has been reported. 70 Radiographically, the tumors are typically those of lytic and destructive lesions not otherwise differing significantly from ordinary chondrosarcoma. Calcified matrix, poor margination, and cortical destruction with an accompanying soft-tissue mass are frequently seen, but some may have well-defined margins with a sclerotic rim. 69, 71 
Pathologic Features
Histologically, the tumor is characterized by a biphasic appearance composed of sheets of primitive small, round, blue cells admixed with variable amount of well-differentiated hyaline cartilage islands (Fig. 11) . The small cell component simulates the cytomorphologic features seen in Ewing sarcoma or lymphoma. A hemangiopericytoma-like vascular pattern is common in the hypercellular, small cell zones. Subtle osteoid production may be occasionally seen. The cartilage nodules vary in size, and may undergo calcification or even ossification. The cartilage may mimic normal chondrogenesis as is seen in the growth plate, or can be indistinguishable from a well-differentiated chondrosarcoma. The interface between the 2 components may be abrupt or gradual. 71 The small cell component of mesenchymal chondrosarcoma is variably positive for CD99. SOX9, a master regulator of chondrogenesis, is positive in both small cell and cartilaginous components of mesenchymal chondrosarcoma in nearly 100% of cases, but negative in other small cell malignancies, including Ewing sarcoma, small cell osteosarcoma, lymphoma, rhabdomyosarcoma, and neuroblastoma. 72, 73 Thus, the marker may serve as a useful tool in the differential diagnosis of small, blue, round cell tumors.
Molecular Genetics
By using a 5 0 RACE technique, a recurrent HEY1-NCOA2 fusion has recently been identified in mesenchymal chondrosarcoma, representing an in-frame fusion of HEY1 exon 4 to NCOA2 exon 13 at the mRNA level. 74 The fusion probably arises through intrachromosomal rearrangement of chromosome 8q. Further, this fusion was detected in all additional tested cases with characteristic histomorphologic features of mesenchymal chondrosarcoma, but was absent in other subtypes of chondrosarcoma. This observation was replicated by 3 later independent studies utilizing Dual-color FISH, sequencing, or RT-PCR analysis. [75] [76] [77] Moreover, t(1;5)(q42;q32) as the sole karyotypic aberration was reported in a single case of mesenchymal chondrosarcoma that lacked a HEY1-NCOA2 fusion. This resulted in a novel fusion between the IRF2BP2 gene and the transcription factor CDX1 gene, thus demonstrating the genetic heterogeneity in this tumor. 76 Notably, IDH1 or IDH2 mutations are frequently harbored in central and periosteal chondromas and chondrosarcomas, but not in other cartilage tumors or other sarcoma types with cartilaginous differentiation (ie, chondroblastic osteosarcoma). [78] [79] [80] These IDH1/2 mutations were not identified in mesenchymal chondrosarcoma. 81, 82 The findings thus far strongly support that the HEY1-NCOA2 fusion is the defining and diagnostic gene fusion, at least for the majority of mesenchymal chondrosarcomas. Surgical resection is the optimal first treatment. Generally, adjuvant chemotherapy is administered after surgery. Mesenchymal chondrosarcoma is an aggressive disease generally with a poor prognosis. Young age and involvement of jaw bones appear to be associated with a slightly better outcome. 69 
SUMMARY
Round cell tumors of bone represent a heterogenous group of neoplasms sharing many histomorphologic similarities and immunophenotypes. These lesions may often demonstrate overlapping clinical and radiologic characteristics, but may have diverse clinical outcomes. While the cell origins of a subset of these tumors remained to be determined, the recent molecular and genetic advancements have enhanced our understanding of their pathogenesis. Our state-of-the-art knowledge has led to reclassification of some of these entities with potential novel therapeutic targets emerging, which will surely influence prognosis significantly.
